VSIR and cancer: Looking at the cancer cells, we observed a reduction in the number of LDHC-silenced cancer cells expressing PD-L1, PD-L2 and CD80, and decrease in the cell surface expression of PD-L2, Gal-9, PVR, HLA-DR and VISTA (Fig. 6A-B, Fig S4C).